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Introduction
Nasopharyngeal carcinoma (NPC) is one of the most 
common head and neck cancers in southern China and 
Southeast Asia [1, 2]. Guangdong province in China and 
Hong Kong have the highest incidence rate around the 
world with incidences ranging from 20 to 22 per 100,000 
men and 8–10 per 100,000 females [3]. The mainstay 
treatment for early NPC patients is radiation therapy [4, 
5]. For locoregionally advanced NPC, using induction 
chemotherapy and concurrent chemo- radiation demon-
strated survival advantage [6, 7]. Of which, therapy using 
platinum- based chemotherapeutic agents such as cisplatin 
shows higher response rate in comparison with the 
nonplatinum therapy [6]. Thus, the resistance of NPC to 
cisplatin will affect the treatment efficacy and prognosis 
of NPC patients.
Existence of tumorigenic cancer cell with stem cell 
property impedes cancer treatment efficacy. These cancer 
stem cells (CSC) had distinct phenotypic features with 
close similarities to normal stem cells. They have adaptive 
advantage to survive in anticancer therapy [8]. In com-
parison to the tumor bulk, the subpopulation of CSC is 
heterogeneous with respect to the responsiveness of chemo-
therapy [8]. Increasing evidence suggests that the resistance 
nature of CSC is a contributory cause leading to cancer 
recurrence [9]. The resting stem cell phenotype makes 
them less responsive to drugs which target preferentially 
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Abstract
Nasopharyngeal carcinoma (NPC) can develop cisplatin- resistant phenotype. 
Research has revealed that enriched in cancer stem cell population is involved 
in developing cisplatin- resistant phenotype. CD271 is a candidate stem cell maker 
in head and neck cancers. The CD receptor does not possess any enzymatic 
property. Signal transduction function of CD271 is mediated by the cellular 
receptor- associated protein. Our data showed that Brain- expressed X- linked 3 
(BEX3), a CD271 receptor- associated protein, was overexpressed in NPC. BEX3 
overexpression was a unique event in cancer developed in the head and neck 
regions, especially NPC. BEX3 expression was inducible by cisplatin in NPC. 
In cisplatin- resistant NPC xenograft, treatment with nontoxic level of cisplatin 
led to a remarkable increase in BEX3 level. High BEX3 expression was accom-
panied with high octamer- binding transcription factor 4 (OCT4) expression in 
cisplatin- resistant NPC. To confirm the inducing role of BEX3 on OCT4 ex-
pression, we knockdown BEX3 using siRNA and compared the expression of 
OCT4 with mock transfectants. Suppressing BEX3 transcripts led to a significant 
reduction in OCT4. In addition, targeting BEX3 using shRNA could increase 
the sensitivity of NPC cells to cisplatin. In summary, our results indicated a 
unique functional role of BEX3 in mediating the sensitivity of NPC cells to 
cisplatin. Targeting or blocking BEX3 activity might be useful in reversing the 
cisplatin- resistant phenotype in NPC.
Cancer Medicine
Open Access
440 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
W. Gao et al.Function of BEX3 in Nasopharyngeal Carcinoma
to actively proliferating cancer cells [10]. In addition, CSC 
had proficient DNA repair capacity with slower cell cycle 
making them less responsive to chemotherapeutic agents 
which target actively proliferating cells [11].
CD271 antigen is a neurotrophin receptor expressed 
on the epithelial stem cell surface. Recent data suggest 
that CD271 is a functional receptor expressed on the 
head and neck CSC [12]. High CD271 expression is 
found in the oral cancer with less differentiated phe-
notype [13]. CD271- positive hypopharyngeal cancer cells 
had higher tumorigenicity than the CD271- negative 
counterparts in vivo and had higher resistance against 
chemotherapy [14]. Increased CD271 expression is asso-
ciated with poor prognosis of patients with oral and 
hypopharyngeal carcinoma [12–14]. At present, whether 
CD271 has any functional and clinical impact on NPC 
remains to be elusive. CD271 itself did not possess any 
enzymatic activity. Signal transduction function of 
CD271 is mediated by the cellular receptor- associated 
protein.
Octamer- binding transcription factor 4 (OCT4) is a 
POU- domain transcription factor. It is a well- known 
stem cell marker and its functional role in mediating 
chemoresistance has been reported in a wide variety of 
human cancers [15–17]. Chemoresistant hepatocellular 
carcinoma (HCC) cell lines with CSC characteristics 
showed a dramatically upregulated expression level of 
OCT4 [15]. Overexpression of OCT4 enhanced the resist-
ance of HCC cells to chemotherapeutic drugs by activating 
AKT signaling pathways. Elevated OCT4 expression was 
observed in oxaliplatin- resistant colorectal cancer (CRC) 
cell lines with CSC properties [16]. OCT4 could activate 
Signal Transducer and Activator of Transcription 3 
(STAT3) pathway, leading to an increase in antiapoptotic 
property of chemoresistant CRC cells. In head and neck 
cancer, forced OCT4 expression promoted the conversion 
of differentiated cells into CSC and conferred resistance 
to cisplatin [17].
To explore the potential clinical implication of CD271 
in NPC, we examined the NPC transcriptome data in 
the public repository. In the pretreatment NPC, CD271 
is not highly expressed. Our data revealed that the 
CD271- associated protein, Brain- expressed X- linked 3 
(BEX3), showed remarkable upregulation in the primary 
NPC. BEX3 expression was inducible in response to 
cisplatin treatment. Furthermore, significant upregulation 
of BEX3 was observed in cisplatin- resistant NPC cells. 
Thus, we proposed that BEX3 overexpression is impor-
tant for the NPC cell to enrich the stemness features 
and acquire cisplatin- resistant phenotype, which thereby 
allows the cancer cells to withstand the stressful envi-
ronment created by the genotoxic chemotherapeutic 
agents.
Materials and Methods
Microarray and in silico analysis
Human cancer microarray meta- analysis was performed 
using CancerMA [18]. The database contains 80 microar-
ray datasets using Affymetrix HG- U133 Plus 2 array from 
ArrayExpress or the GEO repository. These datasets cover 
13 cancer types including adrenal, brain, breast, colorectal, 
head and neck, leukemia, lung, lymphoma, ovarian, pan-
creatic, prostate, renal, and thyroid. Individual datasets 
were normalized and the expression values were computed 
by the ‘affy’ R package from Bioconductor. Subsequently, 
the differentially expressed genes were computed by the 
‘Limma’ R package from Bioconductor and P- values were 
adjusted by the Benjamini and Hochberg’s method. Then, 
a meta- analysis was conducted to combine the results of 
individual datasets for each cancer type and a meta-  P- value 
and a meta- log2- fold change value were calculated. A 
|meta- log2- fold change| >1 or a confidence interval that 
does not span 0, and a meta- P- value <0.05 were con-
sidered as significant. Circos plots and forest plots were 
employed to visualize the analysis results. Oncomine Cancer 
Microarray database was used to analyze the expression 
of BEX3 in NPC tissues and normal tissue counterparts 
[19]. Microarray dataset (GSE12452) containing expression 
data of 31 NPC tissues and 10 normal controls were 
obtained from GEO. The microarray data were normal-
ized and analyzed using Gene Expression Commons [20].
Cell cultures and chemicals
NPC cell lines HONE1 and HK1 were maintained in 
RPMI- 1640 medium supplemented with 10% fetal bovine 
serum, 200 Unit/mL penicillin G sodium, 200 μg/mL 
streptomycin sulfate, and 0.5 μg/mL amphotericin B. 
HONE1 was established from a poorly differentiated NPC. 
HK1 was derived from a well- differentiated NPC [21, 22]. 
Unless specified otherwise, all the chemicals were obtained 
from Sigma.
Immunocytochemistry
NPC cells were fixed with 4% paraformaldehyde and per-
meabilized using 0.25% Triton X- 100 in PBS. 
Immunoreactions were performed using anti- BEX3 (R&D 
Systems, Minneapolis, MN), anti- OCT4 (Santa Cruz, Dallas, 
TX) and anti- CD271 (Santa Cruz) antibodies. CF488- 
conjugated secondary antibodies (Biotium, Fremont, CA) 
was used to develop the signals. Blue- fluorescent 
4’,6- Diamidino- 2- Phenylindole (DAPI, Invitrogen) was 
used to stain the nucleus. F- actin was stained by red- 
fluorescent Alexa Fluor® 635 phalloidin (Invitrogen, Grand 
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Island, NY). Images of the immunostaining were captured 
using fluorescent microscope (Nikon, Tokyo, Japan).
Western blot analysis
Total protein was extracted by RIPA buffer and protein 
concentration was determined by BCA Protein Assay Kit 
(Pierce Biotechnology, Waltham, MA). Protein was sepa-
rated by SDS- PAGE and transferred to polyvinylidene 
difluoride (PVDF) membrane (Millipore, Billerica, MA) 
using semidry method. Then, protein was hybridized to 
anti- BEX3 (R&D Systems), anti- OCT4 (Santa Cruz) and 
anti- CD271 (Santa Cruz) antibodies, followed by incuba-
tion with horse radish peroxidase (HRP) conjugated goat 
anti- mouse IgG (Invitrogen). ECL Plus Western Blotting 
Detection Reagents (Amersham Biosciences, Pittburgh, PA) 
was used to develop hybridization signals.
Real- time quantitative polymerase chain 
reaction
Total RNA was reverse transcribed using High Capacity 
cDNA Reverse Transcription Kit (ABI). Sequences of Real- 
time quantitative polymerase chain reaction (QPCR) prim-
ers were as follows: BEX3 (forward primer: 5′- CTTCG 
GTGCAGTCGTCACT- 3′; reverse primer: 5′- ACACTT 
AGCCTCGCAGACCT- 3′; Universal ProbeLibrary probe 
number 24); OCT4 (forward primer: 5′- CTTCGCAAGC 
CCTCATTTC- 3′; reverse primer: 5′- GAGAAGGCGAAA 
TCCGAAG- 3′; probe number 60). Reactions were per-
formed at 95°C for 10 min followed by 45 cycles of 95°C 
for 15 sec and 60°C for 1 min. Expression levels were 
evaluated using the comparative threshold cycle methods. 
All the reactions were performed using FastStart Universal 
Probe Master (Roche Applied Science) on LightCycler® 
480 (Roche Applied Science). PCR quantification was cal-
culated using 2−ΔΔct method against the glyceraldehyde- 
3- phosphate dehydrogenase (GAPDH) for normalization.
Development of cisplatin- resistant HONE1
The cisplatin- resistant HONE1 cell line was developed by 
chronic treatment of cisplatin. HONE1 was exposed to cis-
platin for 3 days, followed by growth recovery in drug- free 
medium. The concentration of cisplatin was increased in the 
subsequent cycle and the procedure was repeated until resist-
ance was achieved in HONE1. After 21 cycles, the level of 
cisplatin resistance was determined by in vitro toxicity test.
In vitro toxicity test
In vitro toxicity assay was used to confirm the resistance 
level of cisplatin- resistant HONE1 cell line. Relative cell 
viability of cells after cisplatin treatment was determined 
by in vitro Toxicology Assay Kit Sulforhodamine B assay 
(TOX6 from Sigma- Aldrich, St. Louis, MO) according to 
manufacturer’s protocol. The percentage of viability of 
cells was calculated by number of cisplatin- treated viable 
cells / number of viable cells of untreated control.
Colony formation assay
Cells were seeded in a six- well plate with 600 cells in 
each well. After 24 h, cells were treated by cisplatin for 
72 h. After incubation for 14 days, cells were fixed with 
70% ethanol and stained with 0.5% crystal violet. The 
numbers of colonies with more than 50 cells were counted.
Animals
A total of 2 × 106 parental HONE1 or cisplatin- resistant 
HONE1 cells were injected subcutaneously into the right 
flank of athymic nu/nu mice (5 weeks old, weight range: 
18–22 g). Tumor growth was measured daily with calipers 
in two dimensions. Tumor volume was calculated using 
the formula: Volume (in mm3) = (L × W2)/2, where L is 
the length in millimeters and W is the width in millimeters. 
When the tumor volume reached 100 mm3, the mice with 
xenograft derived from parental HONE1 or cisplatin- resistant 
HONE1 were treated by cisplatin. There were five mice in 
each group. Cisplatin (2.5 mg/kg body weight) was admin-
istrated by intraperitoneal injection twice per week. At the 
end point, mice were sacrificed with an excessive dosage 
of pentobarbital and the subcutaneous tumors were removed.
Immunohistochemistry
Mice xenograft were embedded into paraffin blocks and 
cut into 4- μm sections. The sections were dewaxed with 
xylene and rehydrated. Antigen retrieval was achieved by 
microwaving in 10 mmol/L sodium citrate buffer (pH 6.0) 
for 15 min. To block the endogenous peroxidase activity, 
the sections was incubated in 3% hydrogen peroxide for 
10 minutes. Sections were stained with anti- BEX3 antibodies 
(R&D Systems) at room temperature for 1 h. EnVision+ 
System, HRP (DAKO) was used for visualization of immu-
noreaction. Then, sections were counterstained with Mayer’s 
hematoxylin, dehydrated, and photographed under light 
microscope.
SiRNA transfection
BEX3 siRNA, OCT4 siRNA, and negative control siRNA 
were obtained from Qiagen. HiPerFect reagent (QIAGEN, 
Valencia, CA) was used to carry out the transfection reac-
tions according to the manufacturer’s protocol. After 72 h, 
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cells were collected and the efficiency of BEX3 silencing 
was determined by QPCR and Immunocytochemistry.
Lentivirus vector construction, lentivirus 
production, and infection
The oligonucleotides encoding a shRNA specific for BEX3 
were cloned into EcoRI/BamHI sites of pGreenPuro vector 
(System Bioscience). The sense oligonucleotide is: 5’- 
GATCCGGGAGCTGCAGTTGAGGAATTCTTCCTGTC 
AGAAATTCCTCAACTGCAGCTCCCTTTTTG- 3’ and the 
antisense: 5’- AATTCAAAAAGGGAGCTGCAGTTGAGGA
A T T T C T G A C A G G A A G A A T T C C T C A A C T G C A G 
CTCCCG- 3’. Construct sequences were verified by direct 
sequencing. Virus packaging was performed by transient 
transfection into 293T cells using Lipofectamine® 2000 
transfection reagent (Invitrogen). HONE1 cells were trans-
duced with medium containing lentivirus.
Real- time cell kinetic analysis
The xCELLigence RTCA (ACEA Biosciences) was used to 
record the real- time changes of cell proliferation propensity 
of the NPC cells. Data analysis was performed using RTCA 
Control Unit and the preinstalled RTCA software. Cells 
were seeded directly onto E- plate 16. Changes in baseline 
impedance resulting from cell number increase were 
recorded by the microelectrodes. Proportional changes in 
impedance were expressed in cell index (CI).
Statistical analysis
Statistical analysis was performed using SPSS software 
version 20.0. Student t- test was used to compare differ-
ence between groups. All the tests were two- sided. P < 0.05 
was considered as statistically significant.
Results
BEX3 was upregulated in head and neck 
cancers and NPC
To explore the differential expression patterns of BEX 
family members in human malignancies, we performed 
cancer microarray data meta- analysis using CancerMA. 
Expression of BEX1, BEX2, BEX4, and BEX5 were found 
Figure 1. BEX3 was upregulated in head and neck cancers and NPC. (A) Circos plots showing meta- analysis of BEX family members in human 
malignancies using CancerMA. (B) Forest plot showing BEX3 expression in head and neck cancers. NGFRAP1: BEX3. (C) Expression level of BEX3 in 
NPC and normal tissues in GSE12452 from Oncomine. (D) Expression level of BEX3 in NPC and normal tissues in GSE12452 from Gene Expression 
Commons. BEX3, Brain- expressed X- linked 3; NPC, Nasopharyngeal carcinoma.
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to be reduced in different human cancers (Fig. 1A). 
Among the 5 BEX members, BEX3 was the one and 
only one found to be significantly upregulated in head 
and neck cancers (Fig. 1A). Significant overexpression 
of BEX3 is observed in NPC, esophageal squamous cell 
carcinoma (ESCC), oral dysplasia, and oral squamous 
cell carcinoma (OSCC) (Fig. 1B). In comparison with 
all the head and neck datasets, BEX3 in NPC showed 
the highest fold- increase in comparison with the normal 
tissues (Fig. 1B). To confirm our findings, we explored 
BEX3 expression level from NPC dataset in Oncomine. 
Marked overexpression of BEX3 was observed in the 
laser microdissected epithelial carcinoma cells from the 
NPC tissues in GSE12452 (fold change = 2.707, 
P = 2.18E−10; Fig. 1C). Analysis of GSE12452 by Gene 
Expression Commons also confirmed the overexpression 
of BEX3 in NPC tissues (Fig. 1D).
Cisplatin treatment induced the expression 
of BEX3
To investigate the potential role of BEX3 in mediating 
cisplatin resistance, we investigated whether the expression 
of BEX3 was responsive to cisplatin. Cisplatin treatment 
at low concentration induced BEX3 mRNA expression 
in a dose- dependent manner in both HONE1 and HK1 
cells (Fig. 2A). Results from Immunocytochemistry (ICC) 
and western blot showed that cisplatin treatment also 
enhanced the protein expression level of BEX3 (Fig. 2B 
and C).
Figure 2. Cisplatin treatment induced the expression of BEX3. (A) QPCR analysis of mRNA expression level of BEX3 in HONE1 and HK1 cells treated 
with cisplatin. (B) ICC analysis of protein expression level of BEX3 in NPC cells exposed to cisplatin. Blue- fluorescent DAPI was used to stain the 
nucleus. (C) Western blot analysis of protein expression level of BEX3 in NPC cells exposed to cisplatin. Error bar indicate SD, n = 3, *P < 0.05, 
**P < 0.01. Scale bar = 50 μm. BEX3, Brain- expressed X- linked 3; ICC, Immunocytochemistry; NPC, Nasopharyngeal carcinoma; QPCR, Real- time 
quantitative polymerase chain reaction.
(A)
(B)
(C)
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Cisplatin- resistant HONE1 cells exhibited 
higher expression of BEX3, OCT4, and CD271
To explore the functional implications of BEX3 in cisplatin 
resistance, we generated cisplatin- resistant HONE1 by 
chronic treatment with increasing doses of cisplatin. In 
vitro toxicity assay showed that the IC50 value was 3.2- fold 
higher in cisplatin- resistant HONE1 (14.00 ± 1.74 μmol/L) 
than that of parental HONE1 (4.32 ± 0.04 μmol/L, P < 0.01; 
Fig. 3A and B). The cisplatin- resistant HONE1 cells exhib-
ited a spindle- like morphology, indicating a more aggressive 
phenotype (Fig. 3A and B). In colony formation assay, 
no colony was formed in parental HONE1 exposed to 
10 μmol/L cisplatin (Fig. 3C). In contrast, a significantly 
higher number of colony was observed in cisplatin- resistant 
HONE1 after cisplatin treatment compared to parental 
HONE1 (Fig. 3C). Given that CSC contributed to 
resistance to cisplatin treatment, we explored the expres-
sion level of OCT4 (an embryonic stem cell marker) and 
CD271 (a CSC marker) in cisplatin- resistant HONE1. The 
expression levels of BEX3, OCT4 and CD271 were com-
pared in various passages (passage 12 and 21) of cisplatin- 
resistant HONE1. Results from western blot revealed that 
the protein expression levels of BEX3, OCT4 and CD271 
were increased in cisplatin- resistant HONE1 (Fig. 3D). 
QPCR and ICC showed that the mRNA and protein levels 
of BEX3, OCT4, and CD271 were elevated in parallel with 
increasing passage number (Fig. 3E and F).
Cisplatin treatment induced the expression 
of BEX3 in mouse xenograft model
To further study the BEX3- inducing effects of cisplatin in 
vivo, we generated NPC xenograft using parental HONE1 
Figure 3. Cisplatin- resistant HONE1 cells exhibited higher expression of BEX3, OCT4 and CD271. (A, B) In vitro toxicity assay of cisplatin in parental 
and cisplatin- resistant HONE1. The IC50 value was calculated from the dose–response curve. Morphology of parental and cisplatin- resistant HONE1 
was shown by staining of F- actin using red- fluorescent phalloidin. (C) Colony formation assay of parental and cisplatin- resistant HONE1 exposed to 
cisplatin. (D) Western blot analysis of protein expression level of BEX3, OCT4 and CD271 in parental and cisplatin- resistant HONE1. (E, F) QPCR and 
ICC analysis of mRNA and protein expression level of BEX3, OCT4 and CD271 in parental and cisplatin- resistant HONE1. P12, passage 12; P21, 
passage 21. Blue- fluorescent DAPI was used to stain the nucleus. Error bar indicate SD, n = 3, **P < 0.01. Scale bar = 50 μm. BEX3, Brain- expressed 
X- linked 3; ICC, Immunocytochemistry; QPCR, Real- time quantitative polymerase chain reaction.
(µmol/l)
(µmol/l)
µmol/l
µmol/l
(A) (D)
(E)
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or cisplatin- resistant HONE1 and examined the changes of 
BEX3 after exposure to cisplatin. For xenograft derived from 
cisplatin- resistant HONE1, administration of cisplatin at the 
concentration of 2.5 mg/kg body weight for 28 days did 
not have significant impact on xenograft growth, implicating 
the resistance to cisplatin treatment (Fig. 4a). QPCR and 
Immunohistochemistry (IHC) showed that cisplatin treatment 
enhanced the mRNA (Fig. 4B and C) and protein (Fig. 4D 
and E) expression levels of BEX3 in xenograft derived from 
both parental HONE1 and cisplatin- resistant HONE1.
BEX3 regulated the expression of OCT4
Given that high BEX3 expression was accompanied with 
high OCT4 expression in cisplatin- resistant HONE1 cells, 
we investigated the potential role of BEX3 in modulating 
OCT4. Results from ICC, western blot and QPCR revealed 
that transfection of HONE1 and HK1 cells with 15 nM 
BEX3 siRNA successfully reduced the protein (Fig. 5A 
and C) and mRNA (Fig. 5B) levels of BEX3. Silence of 
BEX3 resulted in a significant decrease in protein (Fig. 5D 
and F) and mRNA (Fig. 5E) levels of OCT4.
Figure 4. Cisplatin treatment induced the expression of BEX3 in mouse xenograft model. (A) Growth curve of xenograft derived from cisplatin- 
resistant HONE1 upon cisplatin treatment. There were five mice in each group, Error bar indicate SE. (B, C) QPCR analysis of mRNA expression level 
of BEX3 in xenograft derived from parental HONE1 or cisplatin- resistant HONE1 upon cisplatin treatment. Error bar indicate SD, n = 5, *P < 0.05. (D, 
E) IHC analysis of protein expression level of BEX3 in xenograft derived from parental HONE1 or cisplatin- resistant HONE1 under cisplatin treatment. 
Scale bar = 50 μm. BEX3, Brain- expressed X- linked 3; IHC, Immunohistochemistry; QPCR, Real- time quantitative polymerase chain reaction.
(A) (D)
(E)
(B)
(C)
446 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
W. Gao et al.Function of BEX3 in Nasopharyngeal Carcinoma
BEX3 knockdown sensitized NPC to cisplatin
HONE1 cells containing BEX3- shRNA was generated by 
lentivirus transduction. Downregulation of BEX3 mRNA 
level was observed in HONE1 with BEX3- shRNA (Fig. 6A). 
Results from colony formation assay showed that less 
colonies were observed in BEX3- knockdown cells after 
exposure to 1.0 μmol/L cisplatin (Fig. 6B and C). The 
IC50 value of cisplatin was evaluated by the xCELLigence 
RTCA. Cells were seeded on E- plate and incubated for 
34 h before cisplatin was added to cells. After cisplatin 
treatment for 48 hours, the IC50 value was calculated. 
The IC50 value was significantly lower in HONE1 cells 
containing BEX3- shRNA (3.20 ± 0.40 μmol/L) compared 
to that of mock control (4.78 ± 0.26 μmol/L, P < 0.05; 
Fig. 6D and E).
BEX3 knockdown sensitized cisplatin- 
resistant NPC to cisplatin
Cisplatin- resistant HONE1 with BEX3- shRNA exhibited 
reduced mRNA expression level of BEX3 (Fig. 7A). In 
colony formation assay, BEX3- knockdown cells showed 
less colonies upon cisplatin treatment (Fig. 7B and C). 
The IC50 value of cisplatin was determined by in vitro 
toxicity test. A significant lower IC50 value was observed 
in BEX3- knockdown cells (9.30 ± 0.36 μmol/L) in com-
parison with mock control (14.10 ± 0.65 μmol/L, P < 0.01; 
Fig. 7D).
Knockdown of OCT4 enhanced the 
sensitivity of NPC to cisplatin
The mRNA (Fig. 8A) and protein (Fig. 8B) expression 
levels of OCT4 were significantly decreased in HONE1 
cells transfected with OCT4 siRNA. Under cisplatin treat-
ment, the IC50 value of OCT4- knockdown cells 
(2.80 ± 0.03 μmol/L) was significantly lower than mock 
control (4.72 ± 0.12 μmol/L, P < 0.01; Fig. 8C).
Discussion
NPC patients suffering from relapse to therapy or recur-
rent disease are resistant to the conventional therapy with 
Figure 5. BEX3 regulated the expression of OCT4. (A, B) ICC and QPCR analysis of protein and mRNA expression level of BEX3 in HONE1 and HK1 
cells transfected with BEX3 siRNA. (C) Western blot analysis of protein expression level of BEX3 in HONE1 and HK1 cells transfected with BEX3 siRNA. 
(D, E) ICC and QPCR analysis of protein and mRNA expression level of OCT4 in NPC cells transfected with BEX3 siRNA. Blue- fluorescent DAPI was used 
to stain the nucleus. (F) Western blot analysis of protein expression level of OCT4 in HONE1 and HK1 cells transfected with BEX3 siRNA. Error bar 
indicate SD, n = 3, **P < 0.01. Scale bar = 50 μm. BEX3, Brain- expressed X- linked 3; ICC, Immunocytochemistry; DAPI, 6- Diamidino- 2- Phenylindole; 
NPC, Nasopharyngeal carcinoma; QPCR, Real- time quantitative polymerase chain reaction.
(A) (B)
(C)
(D) (E)
(F)
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radiation or chemotherapeutic drugs [23]. Stimulation 
from the tumor microenvironment shapes the develop-
ment of CSC and development of resistance against 
chemotherapy. Cancer cells can be induced to acquire 
the stem cell phenotype under chronic chemotherapeutic 
stress. Chemotherapeutic drugs can trigger adaptive 
response at multiple levels and promote cancer cells to 
acquire stem cell phenotype in order to potentiate survival 
in the stressful environment.
Cis- diamminedichloroplatinum (II) or cisplatin is a 
platinum- based genotoxic drug used most often in the 
treatment of NPC with satisfactory response rate [24]. 
Cisplatin could render cell cycle arrest and induce apop-
tosis by forming adducts with the DNA of the cancer 
cells. Cisplatin- based chemotherapy has been shown to 
improve the overall and progression- free survival of NPC 
patients [25, 26]. Nevertheless, treatment failure is not 
uncommon as the cancer may be inherent resistant to 
cisplatin or acquire resistant phenotype during the course 
of treatment [27]. Patients typically develop cisplatin resist-
ance within 2 years of initial treatment leading to poor 
prognosis. At present, there is still no effective pharma-
cological manipulation available to circumvent the 
problem.
Figure 6. BEX3 knockdown sensitized NPC to cisplatin. (A) QPCR analysis of mRNA expression level of BEX3 in HONE1 with BEX3- shRNA. (B, C) 
Colony formation of BEX3- knockdown HONE1 cells after exposure to 1.0 μmol/L cisplatin. (D, E) Real- time cell kinetic analysis of cisplatin cytotoxicity 
using xCELLigence RTCA. Cisplatin was added to BEX3- knockdown HONE1 cells and cell index was continuously monitored. The IC50 value was 
calculated from the dose–response curve after cisplatin treatment for 48 h. Error bar indicate SD, n = 3, **P < 0.01. BEX3, Brain- expressed X- linked 
3; ICC, Immunocytochemistry; NPC, Nasopharyngeal carcinoma; QPCR, Real- time quantitative polymerase chain reaction.
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CD271 is expressed at high level in embryonic stem 
cells and adult stem cells. In oral epithelia cancer, high 
CD271 expression is associated with poor prognosis [28]. 
CD271 do not have any intrinsic enzymatic property. The 
signal transduction functions are achieved by recruiting 
intracellular proteins which interact with the intracellular 
domains of CD271 [29]. Hence, identifying and evaluating 
key receptor- associated protein is important to understand 
the functional implication of CD271 in regulating thera-
peutic sensitivity.
In normal neuronal cells, multiple CD271 binding pro-
teins have been identified. The interactions between dif-
ferent receptor- associated protein could regulate different 
signal cascade and control multiple cellular processes 
including cell cycle, migration, invasion, and apoptosis 
[29]. Our results showed that BEX3, the receptor- associated 
protein, is significantly increased in NPC tissues. BEX3 
expression is further increased in response to cisplatin 
treatment. The association of BEX3 in cisplatin resistance 
is further confirmed with the established cisplatin- resistant 
cell line. Overall, the results suggested that upregulating 
Figure 7. BEX3 knockdown sensitized cisplatin- resistant NPC to cisplatin. (A) QPCR analysis of mRNA expression level of BEX3 in cisplatin- resistant 
HONE1 with BEX3- shRNA. (B, C) Colony formation of cisplatin- resistant HONE1 cells with BEX3- shRNA upon cisplatin treatment. (D) Dose–response 
curve of cisplatin- resistant HONE1 with BEX3- shRNA and mock control cells under cisplatin treatment. The IC50 value of cisplatin was calculated from 
dose–response curve. Error bar indicate SD, n = 3, **P < 0.01. BEX3, Brain- expressed X- linked 3; ICC, Immunocytochemistry; QPCR, Real- time 
quantitative polymerase chain reaction.
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Figure 8. OCT4 knockdown sensitized NPC to cisplatin. (A) QPCR 
analysis of mRNA expression level of OCT4 in HONE1 transfected with 
OCT4 siRNA. (B) Western blot analysis of protein expression level of 
OCT4 in HONE1 transfected with OCT4 siRNA. (C) Dose–response curve 
of OCT4- knockdown HONE1 and mock control cells under cisplatin 
treatment. The IC50 value of cisplatin was calculated from dose–response 
curve. Error bar indicate SD, n = 3, **P < 0.01. NPC, Nasopharyngeal 
carcinoma; QPCR, Real- time quantitative polymerase chain reaction.
(A)
(C)
(B)
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BEX3 expression is important for the NPC cells to response 
to the genotoxic stress introduced by cisplatin.
The functional implications of BEX3 in cancers remained 
unresolved. At present, most studies on normal neural 
originated cells suggest that BEX3 is a proapoptotic gene 
[30]. In normal cells, BEX3 is known as a cell death 
executor as it could mediate cell death in the presence 
of CD271 ligand [31]. In cultured cortical neurons, BEX3 
could induce caspase- dependent neuronal apoptosis [32]. 
In breast cancers, BEX3 promoted apoptosis and inhibited 
mouse xenograft formation [33]. On the contrary, several 
studies showed the prosurvival role of BEX3. Silence of 
BEX3 reduced the survival of nerve growth factor (NGF)- 
dependent neurons by inhibiting the expression of tyrosine 
kinase receptor A of NGF [34]. In F9 teratocarcinoma 
cells, knockdown the expression of BEX3 suppressed cell 
growth [35]. Thus, high expression of BEX3 in NPC with 
uncontrolled proliferative capability seems to be contra-
dicting with the proposed functions in cell death. To 
explore expression patterns of BEX family in human 
malignancies, we performed microarray meta- analysis on 
13 cancer types. The results indicated that BEX3 upregu-
lation is only limited on cancers originated in head and 
neck. Upregulation is not observed on other cancer types 
including adrenal, brain, breast colorectal, leukemia, lung, 
lymphoma, ovarian, pancreatic, prostate, renal, and thyroid. 
The data reveal that BEX3 overexpression is dependent 
on cell context. The confined distribution in the human 
cancers indicated that BEX3 is playing a unique role in 
the pathogenesis of cancers in head and neck regions 
including NPC.
As shown in Oct4- inducible mice, continuous Oct4 
expression in epithelial tissues could lead to dysplastic 
growth suggesting that high Oct4 may account for the 
cancerous changes of the epithelial layers [36]. Exogenous 
expression of OCT4 could increase the tumor- initiating 
and colonization capabilities of cancer cells [37]. In non-
cancerous head and neck epithelia, OCT4 expression level 
is beyond the detection limit and could only be detected 
in the basal layer [38]. In NPC tissue, however, OCT4 
is overexpressed with high level detected at the invasive 
front of the cancer tissues and is associated with the poor 
overall survival of NPC patients [38]. OCT4 expression 
is enriched in NPC with stem cell characteristics [39]. 
NPC with high sphere forming ability exhibited signifi-
cantly higher OCT4 expression [40].
In summary, our results indicate that BEX3 expression 
is linked with cisplatin sensitivity of NPC. Targeting BEX3 
might be clinically useful for sensitizing NPC to cisplatin- 
based chemotherapy. Further studies on the functional 
role of BEX3 are warranted for developing the potential 
therapeutic use of BEX3 as molecular target in NPC 
treatment.
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